SparingVision is a clinical-stage genomic medicines company that develops treatments for ocular diseases. The company focuses on moving beyond single gene correction therapies to deliver new treatments to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.

SparingVision

SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. 

At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause. 

The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.

Intellia Therapeutics

4BIO Capital

Foundation Fighting Blindness

Jeito Capital

Ysios Capital

UPMC Enterprises

Retinal Degeneration Fund

Bpifrance

✨ As we gear up for the Paris 2024 Paralympics taking place from 28 August – 8 September, we’re excited to witness the incredible talents of the over 4,400 participating athletes 🏅

Among them, visually impaired athletes will showcase their resilience and determination across various sports, including goalball, blind football, para-track, swimming, 🏊♂️ rowing, judo, 🤼♂️ cycling 🚴♀️ triathlon and horseback riding.

💪 Let’s show these incredible athletes our support by cheering them on and celebrating their achievements as they inspire us all to embrace inclusivity in sport and beyond! 🙌

#Paris2024 #Paralympics #RP #VisualImpairment

📣 #ICYMI – Discover the list of upcoming conferences the SparingVision management team will be attending in the second half of 2024 ⬇️

https://lnkd.in/eWDhe-Mz 
 
#Events #SPVN #Ophthalmology #GeneTherapy

✨ Recently we have had the pleasure of welcoming new members to the SparingVision team across the world! 🌍

This includes Diana Cepeda, VP of R&D, Anthony Ramirez, VP of CMC, Alaric Falcon, Director R&D Operations, Morgane Caille, Associate Director, Quality Assurance and Pauline Jacquety Senior Manager, Regulatory Affairs. 

Welcome to the team! 🎉

#SparingVision #NewHires

This #NationalEyeExamMonth, test your Inherited Retinal Disease (IRD) knowledge! 👁️

Tomorrow, Daniel C. Chung, DO, MA, CMO, and Nathalie Delair-Trepo, VP, IR and Communications will be attending the Barclays Biotech: 1x1 Private Company Symposium, taking place August 7, 2024.
 
We’re looking forward to interacting with dedicated biotech investors in virtual one-on-one meetings and sharing the latest advancements in genomic medicines and ophthalmology!
 
 Learn more here: https://lnkd.in/ezaQPe_M
 
#Ophthalmology #GenomicMedicines #GeneEditing #RetinalDiseases

👁️ August #NationalEyeExamMonth in the US, an initiative that reminds us to protect our vision by scheduling routine eye examinations.
 
❗Retinitis Pigmentosa (RP) is a highly prevalent group of related eye disorders that impacts an estimated 2 million patients worldwide and is caused by variations in any one of more than 80 genes that affect the retina.
 
Comprehensive dilated eye exams and genetic testing can be used to identify RP early, allowing for timely intervention.
 
Our Phase I/II clinical trial, PRODYGY, is currently ongoing in France and the US to assess the safety, tolerability as well as preliminary efficacy and quality-of-life of our lead gene therapy approach for RP, SPVN06.
 
Learn more about the progress of SPVN06 here: https://lnkd.in/gXHsfYrA 
 
#GenomicMedicines #GeneTherapy #GenomeEditing #Ophthalmology #RetinalDiseases

We would like to congratulate our co-founder José-Alain Sahel for being awarded the Wolf Prize for Medicine by the Wolf Foundation.
 
The Wolf Prize is awarded annually and honors exceptional individuals who transcend barriers of religion, gender, race, geography, and political stance - acknowledging scientists and artists worldwide for their outstanding achievements in advancing science and the arts for the betterment of humanity.
 
Congratulations to all laureates of 2024!
 
#WolfFoundation #WolfPrize #Ophthalmology #GeneTherapy #GenomicMedicines

🌟 Tomorrow, Daniel C. Chung, DO, MA, Chief Medical Officer, will be attending the 42nd American Society of Retina Specialists (#ASRS) Annual Scientific Meeting in Stockholm, Sweden, taking place from 17-20 July. 👁️

🔬 We’re looking forward to immersing ourselves in the conference and discovering advancements in retina science, therapeutics, and innovation! ✨

Hope to see you there! 🙌

https://lnkd.in/emA4Eur 

#Ophthalmology #GeneTherapy #SparingVision #SPVN06 #GenomicMedicines

🚀 SparingVision will be participating in the ARM Cell & Gene Congressional Fly-In, taking place on July 15-16, 2024, in Washington, D.C.! 🏛️

This event, organized by the Alliance for Regenerative Medicine, brings together leaders in the cell and gene therapy sector to advocate for enhanced patient access to these transformative treatments. 🧬

Our Chief Medical Officer, Daniel C. Chung, DO, MA, will join other industry representatives to engage with policymakers on Capitol Hill, share our insights, and champion the future of regenerative medicine. 💡

✨ We look forward to discussing the latest developments in our field and collaborating with other advocates to drive meaningful change that support innovation and patient care.

#RegenerativeMedicine #GeneTherapy #CellTherapy #Innovation #Advocacy #Healthcare

🌟 June has been an action-packed month for SparingVision! 

The medical team been actively engaging with the global scientific community, sharing our latest advancements, and participating in key industry events. 

From impactful presentations to collaborative discussions, our team is continuing to pioneer cutting-edge genomic technologies that transform the treatment of retinal disease. Stay tuned for more! 🚀 

#Ophthalmology #RetinalResearch #SparingVision

SPAR

COM:SPARINGVISION

SparingVision

name

homepage url

country

linkedin url

sector

industry

Description

peer of

Metrics